secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ovid Therapeutics Inc. (OVID)
CIK:        0001636651
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001636651-25-000011
Event type: leadership
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ovid Therapeutics announces CEO succession, Q3 2025 loss, and pipeline progress
-------------------------------------------------------------------------------

- Meg Alexander appointed CEO effective Jan 1, 2026; Jeremy Levin to become Executive Chairman.
- Q3 2025 net loss $12.2M ($0.17/sh) vs $14.0M ($0.20) YoY; cash $25.6M at Sep 30.
- Completed $81M private placement (up to $175M); cash runway extended into 2H 2028.
- OV329 Phase 1 positive; Phase 2a in drug-resistant epilepsies planned Q2 2026.
- OV350 IV data expected Q4 2025; OV4071 oral KCC2 activator to enter clinic Q2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636651/000163665125000011/0001636651-25-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636651/000163665125000011/ovid-20251112.htm
  HTML page:      https://secwatch.observer/filing/0001636651-25-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer